Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva’s Rosy View For A Happy Union With Allergan Generics

Executive Summary

The company provided updated mid-term guidance for the combined company, net revenues of $26.7bn to $27.8bn and EBITDA of $10.7bn to $11.5bn in 2019. The deal is expected to close any day, management assured investors.

Advertisement

Related Content

Stockwatch: Teva, Biogen, Ionis, Sage And The Art Of Strategic News Placement
Teva Advancing Two Advair Generics With Late 2017 Target
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
Teva Continues Divestitures To Close Allergan Deal With Sale To Impax
Teva’s Allergan Generics Buy Progressing, Though Timeline Might Slip
Teva to buy Allergan Generics; Mylan off the hook but Perrigo still wriggling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel